Eli Lilly & Co. to expand prescription drug assistance programs
INDIANAPOLIS Drug maker Eli Lilly & Co. announced Wednesday an expansion of its prescription drug assistance programs.
Lilly USA adjusted the income eligibility for one of its patient assistance programs to allow enrollment of eligible patients who make incomes of 300% or less of the U.S. Federal Poverty Level, compared to 200% before the change.
“By making these changes, we are addressing a real concern for patients we have heard from in recent months,” Lilly CEO John Lechleiter said in a statement. “Many have lost their jobs and insurance coverage and need our help to stay on their medications.”
Lilly’s programs include Lilly Cares, which allows eligible patients to obtain free medicines; LillyMedicareAnswers, which provides some Medicare recipients access to Lilly drugs outside their Medicare Part D plans; and Lilly Specialty Programs, which provides specialty products.
Par reports increase in revenue, income and EPS for Q2
WOODCLIFF LAKE, N.J. Generic drug maker Par Pharmaceutical Cos. got a jump in revenues and net income during second quarter 2009, the company announced in an earnings report Tuesday.
Par reported total revenues of $404 million, net income of $23.8 million and diluted earnings per share of 71 cents. This compared with reported revenues of $112.9 million, a net loss of $21.2 million and diluted earnings per share of 64 cents during second quarter 2008.
The company also saw increases in product sales. Sales of the heart disease drug metoprolol succinate – an authorized generic version of AstraZeneca’s Toprol XL – were $306 million during the quarter, a 173% increase over first quarter 2009. The injected migraine headache drug sumatriptan, a generic version of GlaxoSmithKline’s Imitrex, had sales of $21.8 million, compared to $16 million during the first quarter.
Meanwhile, the antihistamine meclizine, a generic version of Pfizer’s Antivert, was $8.9 million, compared with $9.8 million during first quarter, the decrease resulting primarily from trade buying patterns.
FlavorX Flavoring System helps the medicine go down
BOSTON Mary Poppins may have observed a spoonful of sugar’s ability to help wash medicine down, but a mouthful of bitter syrup continues to be an unpleasant experience for any child.
FlavorX, a company based in the Baltimore and Washington area, has designed an automation dispensing aid designed to improve the palatability of medicines for children.
The FlavorX Flavoring System uses a bitterness suppressor and sweetness enhancer to allow pharmacists to mask the taste of many prescription and OTC medications in a wide variety of flavors, speeding up the flavoring process while giving the pharmacist complete control of the process.
According to some research, 86% of parents found that flavoring by the pharmacist influenced children’s success in taking the asthma drug prednisone, while 40% of children completed their therapies without flavoring.
“These figures clearly illustrate that flavoring medications promotes better patient compliance and increases positive clinical outcomes,” FlavorX president and CEO Stuart Amos said in a statement. “We wanted to help pharmacists fill a flavored prescription faster and meet the increasing demand as well as help patients get well.”